Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of osimertinib combinations with savolitinib or selumetinib in EGFR-mutant advanced non-small cell lung cancer after EGFR TKI progression
jRCT2080222610Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of osimertinib, savolitinib and selumetinib in non-small cell lung cancer (NSCLC) and Non-hematologic malignancy (7 arms), sponsored by AstraZeneca. Primary endpoints: Safety, Tolerability and 1 more. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080222610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222610.